<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6563844\results\search\drugs\results.xml">
  <result pre="and diluted in either water, phosphate buffer saline (PBS), or" exact="dimethyl sulfoxide" post="(DMSO, Sigma) to stock concentrations of 0.5 M, and"/>
  <result pre="following doses used in all mouse experiments: 50 mg/kg/day for" exact="oseltamivir" post="phosphate, 40 mg/kg/day for naltrexone, 100 mg/kg/day gallium nitrate,"/>
  <result pre="virus strains were treated orally every 8 h with either" exact="oseltamivir" post="(2.5 mg/kg, Roche) or dextromethorphan (2 mg/kg, Procter, &amp;amp;"/>
  <result pre="infection, or left untreated. For infection, animals were anesthetized with" exact="ketamine" post="and medetomidine (2/0.2 mg/kg), and then inoculated intranasally with"/>
  <result pre="left untreated. For infection, animals were anesthetized with ketamine and" exact="medetomidine" post="(2/0.2 mg/kg), and then inoculated intranasally with 1 ×"/>
  <result pre="activity at a 10-fold lower concentration (Table 1). Adenosine triphosphate," exact="etidronic acid," post="N-acetyl-D-glucosamine, L-glutamic acid, thalidomide, amiloride, and dacarbazine had no"/>
  <result pre="A/Mexico/InDRE4487/2009 (H1N1pdm09) were included in the study. The neuraminidase inhibitor" exact="oseltamivir" post="carboxylate was used as a positive control. Using the"/>
  <result pre="setup with 10-fold decreasing drug concentrations starting at 500 μM," exact="oseltamivir" post="carboxylate completely inhibited replication of all three strains at"/>
  <result pre="ranged from around 10-fold for gallium nitrate to 100-fold for" exact="naltrexone" post="and ketotifen, and around 1,000-fold for dextromethorphan. While the"/>
  <result pre="drug concentrations, again starting at 500 μM, the EC50 of" exact="oseltamivir" post="carboxylate ranged between 5 and 200 nM, with PR8"/>
  <result pre="MDCK cells using an MTT assay. While the SI for" exact="oseltamivir" post="carboxylate was between 2,000 and 100,000, the SI for"/>
  <result pre="still lowered lung viral titers around 8- to 10-fold, while" exact="naltrexone" post="and gallium nitrate treatments had no significant effect (Figure"/>
  <result pre="infection. In this series of experiments, the inhibitory effect of" exact="ketotifen" post="alone was even less pronounced, and there was no"/>
  <result pre="even less pronounced, and there was no additive effect when" exact="ketotifen" post="and dextromethorphan were combined. Combination of each of the"/>
  <result pre="dextromethorphan were combined. Combination of each of the drugs with" exact="oseltamivir" post="resulted in a slight, but non-significant increase in inhibition,"/>
  <result pre="combined, the inhibitory effect was significantly higher than that of" exact="oseltamivir" post="alone (Figure 3B), suggesting a modest benefit of combination"/>
  <result pre="oral dextromethorphan formulation at a dose of 2 mg/kg, or" exact="oseltamivir" post="solution at a dose of 2.5 mg/kg. This schedule"/>
  <result pre="twice daily for weight loss, temperature, and clinical signs. While" exact="oseltamivir" post="phosphate treatment resulted in a 10-fold reduction in nasal"/>
  <result pre="whereas there was no reduction in body weight in the" exact="oseltamivir" post="group (Figure 4B). In the control group, clinical signs"/>
  <result pre="4C). Even though the effect was less pronounced compared to" exact="oseltamivir" post="phosphate treatment, which only resulted in a minimal clinical"/>
  <result pre="of viral titers in vitro, but also in mice. While" exact="ketotifen" post="blocks histamine H1 receptors and the release of inflammatory"/>
  <result pre="to opioid-containing cough suppressants (51, 52). The antiviral properties of" exact="ketotifen" post="may thus be associated with its anti-inflammatory effect (39),"/>
  <result pre="differences in disease severity and pathological and virological parameters. While" exact="oseltamivir" post="reduced viral load and clinical disease, and prevented weight"/>
  <result pre="warranted to evaluate if combination treatment increases the efficacy of" exact="oseltamivir" post="or other virus-targeting drugs, especially when treatment is started"/>
  <result pre="technologies. J Clin Pharmacol. (2014) 54:719–31. 10.1002/jcph.29924691877 10.IntharathepPLaohpongspaisanCRungrotmongkolTLoisruangsinAMalaisreeMDechaPet al.. How" exact="amantadine" post="and rimantadine inhibit proton transport in the M2 protein"/>
  <result pre="Clin Pharmacol. (2014) 54:719–31. 10.1002/jcph.29924691877 10.IntharathepPLaohpongspaisanCRungrotmongkolTLoisruangsinAMalaisreeMDechaPet al.. How amantadine and" exact="rimantadine" post="inhibit proton transport in the M2 protein channel. J"/>
  <result pre="viruses. Antimicrobial Agents Chemother. (2010) 54:2517–24. 10.1128/AAC.01739-0920350949 29.TomieAAzoguIYuL. Effects of" exact="naltrexone" post="on post-abstinence alcohol drinking in C57BL/6NCRL and DBA/2J mice."/>
  <result pre="10.1093/cvr/cvp04319189960 41.SmeeDFHurstBLWongMHBaileyKWMorreyJD. Effects of double combinations of amantadine, oseltamivir, and" exact="ribavirin" post="on influenza A (H5N1) virus infections in cell culture"/>
  <result pre="and cell survival. Cell. (2007) 131:596–610. 10.1016/j.cell.2007.08.03617981125 58.OchiaiHKurokawaMNiwayamaS. Influence of" exact="trifluoperazine" post="on the late stage of influenza virus infection in"/>
 </snippets>
</snippetsTree>
